您当前所在的位置:首页 > 产品中心 > 产品详细信息
78415-72-2 分子结构
点击图片或这里关闭

6-methyl-2-oxo-5-(pyridin-4-yl)-1,2-dihydropyridine-3-carbonitrile

ChemBase编号:120
分子式:C12H9N3O
平均质量:211.21936
单一同位素质量:211.07456192
SMILES和InChIs

SMILES:
O=c1[nH]c(c(c2ccncc2)cc1C#N)C
Canonical SMILES:
N#Cc1cc(c2ccncc2)c([nH]c1=O)C
InChI:
InChI=1S/C12H9N3O/c1-8-11(9-2-4-14-5-3-9)6-10(7-13)12(16)15-8/h2-6H,1H3,(H,15,16)
InChIKey:
PZRHRDRVRGEVNW-UHFFFAOYSA-N

引用这个纪录

CBID:120 http://www.chembase.cn/molecule-120.html

Collapse All Expand All

名称和登记号

名称和登记号

名称 登记号
IUPAC标准名
6-methyl-2-oxo-5-(pyridin-4-yl)-1,2-dihydropyridine-3-carbonitrile
IUPAC传统名
milrinone
商标名
Corotrop
Corotrope
Milrila
Primacor
别名
Milrinone Lactate
Milrinone
1,6-Dihydro-2-methyl-6-oxo-3,4-bipyridine-5-carbonitrile
1,6-Dihydro-2-methyl-6-oxo-(3,4′-bipyridine)-5-carbonitrile
Milrinone
1,6-Dihydro-2-methyl-6-oxo-[3,4'-bipyridine]-5-carbonitrile
Corotrope
Milrila
Win 47203
Primacor
CAS号
78415-72-2
EC号
278-903-6
MDL号
MFCD00133539
PubChem SID
160963583
24278060
46507838
PubChem CID
4197

理论计算性质

理论计算性质

JChem ALOGPS 2.1
Acid pKa 7.536811  质子受体
质子供体 LogD (pH = 5.5) 0.2525552 
LogD (pH = 7.4) 0.12443696  Log P 0.3290194 
摩尔折射率 61.1381 cm3 极化性 22.2292 Å3
极化表面积 65.78 Å2 可自由旋转的化学键
里宾斯基五规则 true 
Log P 1.04  LOG S -3.0 
溶解度 2.09e-01 g/l 

分子性质

分子性质

理化性质 安全信息 药理学性质 产品相关信息 生物活性(PubChem)
溶解度
DMSO expand 查看数据来源
DMSO: >10 mg/mL expand 查看数据来源
H2O: insoluble expand 查看数据来源
Slightly soluble expand 查看数据来源
外观
off-white powder expand 查看数据来源
Off-White Solid expand 查看数据来源
熔点
305-308°C (dec.) expand 查看数据来源
密度
0.87 g/ml expand 查看数据来源
疏水性(logP)
0.4 expand 查看数据来源
保存条件
-20°C expand 查看数据来源
Refrigerator expand 查看数据来源
RTECS编号
DW1762000 expand 查看数据来源
欧盟危险性物质标志
有毒(Toxic) 有毒(Toxic) (T) expand 查看数据来源
联合国危险货物编号
2811 expand 查看数据来源
MSDS下载
下载链接 expand 查看数据来源
下载链接 expand 查看数据来源
德国WGK号
3 expand 查看数据来源
联合国危险货物等级
6.1 expand 查看数据来源
联合国危险货物包装类别(PG)
3 expand 查看数据来源
III expand 查看数据来源
澳大利亚Hazchem
2X expand 查看数据来源
危险公开号
23/24/25 expand 查看数据来源
R:25 expand 查看数据来源
安全公开号
36/37/39-45 expand 查看数据来源
S:28-29-36/37/39-45 expand 查看数据来源
欧盟危险货物分类
T2 expand 查看数据来源
欧盟危险识别号(EUHIN)
6.1B expand 查看数据来源
美国ERG指导号
154 expand 查看数据来源
GHS危险品标识
GHS06 expand 查看数据来源
GHS警示词
Danger expand 查看数据来源
GHS危险声明
H301-H311-H331 expand 查看数据来源
GHS警示性声明
P261-P280-P301 + P310-P311 expand 查看数据来源
个人保护装置
Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges expand 查看数据来源
RID/ADR
UN 2811 6.1/PG 3 expand 查看数据来源
保存温度
2-8°C expand 查看数据来源
相关基因信息
human ... PDE3A(5139), PDE3B(5140), PDE4B(5142), PDE5A(8654), PTPRA(5786)rat ... Pde3a(50678) expand 查看数据来源
纯度
≥97% (TLC) expand 查看数据来源
97% expand 查看数据来源
成盐信息
Free Base expand 查看数据来源
质检报告
下载链接 expand 查看数据来源
下载链接 expand 查看数据来源

详细说明

详细说明

DrugBank DrugBank MP Biomedicals MP Biomedicals Selleck Chemicals Selleck Chemicals Sigma Aldrich Sigma Aldrich TRC TRC
DrugBank -  DB00235 external link
Item Information
Drug Groups approved
Description A positive inotropic cardiotonic agent with vasodilator properties. It inhibits cAMP phosphodiesterase activity in myocardium and vascular smooth muscle. Milrinone is a derivative of amrinone and has 20-30 times the ionotropic potency of amrinone. [PubChem]
Indication Indicated for the treatment of congestive heart failure.
Pharmacology Milrinone, a synthetic dimethylxanthine derivative structurally related to theophylline and caffeine, is used in the treatment of peripheral vascular diseases and in the management of cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy.
Toxicity LD50 = 0.3 mg/L in rats
Affected Organisms
Humans and other mammals
Biotransformation There are five metabolites but the O-glucuronide represents the major pathway of biotransformation.
Absorption Milrinone is rapidly and almost completely absorbed after oral administration. Bioavailability is 92% (in healthy volunteers).
Half Life 2.3 hours
Protein Binding 70 to 80%
Elimination The primary route of excretion of milrinone in man is via the urine.
Distribution * 0.38 liters/kg [intravenous injections of 12.5 mcg/kg to 125 mcg/kg to congestive heart failure patients]
* 0.45 liters/kg [intravenous infusions of 0.20 mcg/kg/min to 0.70 mcg/kg/min to congestive heart failure patients]
Clearance * 0.13 L/kg/hr [congestive heart failure patients, following IV injections of 12.5 mcg/kg to 125 mcg/kg]
* 0.14 L/kg/hr [congestive heart failure patients, following infusions of 0.2 mcg/kg/min to 0.7 mcg/kg/min]
External Links
Wikipedia
RxList
Drugs.com
MP Biomedicals -  02158962 external link
Purity: 97%
Specifically inhibits cGMP-inhibited phosphodiesterase. Strong cardiotonic positive inotropic vasodilator.
Selleck Chemicals -  S2484 external link
Research Area: Cardiovascular Disease
Biological Activity:
Milrinone(Primacor) is a a potent and selective phosphodiesterase 3 inhibitor with an IC50 of 0.42 µM for the inhibition of FIII PDE. [1] It potentiates the effect of cyclic adenosine monophosphate (cAMP). It also enhances relaxation of the left ventricle by increasing Ca2+-ATPase activity on the cardiac sarcoplasmic reticulum. This increases calcium ion uptake.It has positive inotropic, vasodilating and minimal chronotropic effects. It is used in the management of heart failure only when conventional treatment with vasodilators and diuretics has proven insufficient. This is due to the potentially fatal adverse effects of milrinone, including ventricular arrhythmias. [2]
Sigma Aldrich -  M4659 external link
Biochem/physiol Actions
Phosphodiesterase type III inhibitor; cAMP-specific, cGMP-inhibitable; potent cardiotonic, positive inotropic vasodilator.
Toronto Research Chemicals -  M344680 external link
Selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity. Cardiotonic.

参考文献

参考文献

供应商提供 Google Scholar IconGoogle Scholar PubMed iconPubMed Google Books IconGoogle Books
  • Alousi, A.A., et al.: J. Cardiovasc Pharmacol., 5, 792 (1983)
  • Maskin, C.S., et al.: Circulation, 67, 1065 (1983)
  • Sinoway, L.S., et al.: J. Am. Coll. Cardiol., 2, 327 (1983)
  • Baim, D.S., et al.: N. Engl. J. Med., 309, 748 (1983)
  • Ito M et al. Biochem Pharmacol. 1988 May 15;37(10)
  • Harrison, S.A., et al., Mol. Pharmacol. , 29 : 506 (1986).
  • Ahn, S., et al., Biochem. Pharmacol. , 35 : 1113 (1986).
  • Alousi, A.A., et al., J. Cardiovas. Pharmacol. , 5 : 792 (1983).
正在搜索,请耐心等待...(如果遇到网页错误或者长时间没有结果,请刷新页面[F5])

专利

专利

PubChem iconPubChem Patent Google Patent Search IconGoogle Patent

互联网资源

互联网资源

百度图标百度 google iconGoogle